艾米替诺福韦联合甘草酸二铵治疗慢性乙型肝炎患者临床疗效研究*

doi:10.3969/j.issn.1672-5069.2026.01.007

摘要/Abstract

摘要： 目的探讨艾米替诺福韦联合甘草酸二铵治疗慢性乙型肝炎(CHB)患者的临床疗效。方法 2022年6月～2024年6月我院诊治的CHB患者112例,被随机分为对照组56例和观察组56例,分别给予艾米替诺福韦或艾米替诺福韦联合甘草酸二铵治疗48周。采用荧光定量PCR法检测血清HBV DNA定量,常规行血液和血清检测,计算肝纤维化4因子指数(FIB-4),使用肝脏弹性成像仪行肝硬度检测(LSM)。结果在治疗前,观察组和对照组血清HBV DNA载量为(7.3±1.2)lg copies/mL和(7.5±1.3)lg copies/mL(P>0.05),在治疗48周末,两组分别为(1.3±0.2)lg copies/mL和(1.3±0.3)lg copies/mL(P>0.05),两组血清HBV DNA转阴率均为100.0%(P>0.05);观察组血清ALT和AST水平分别为(39.6±1.1)U/L和(34.2±14.5)U/L,均显著低于对照组【分别为(54.2±5.6)U/L和(43.8±16.3)U/L,P＜0.05】;观察组FIB-4为(1.8±0.3),显著低于对照组的【(2.1±0.4),P＜0.05】,而两组LSM【(6.7±1.0)kPa对(6.8±1.3)kPa】比较,无显著性差异(P>0.05);两组药物不良反应发生率(17.9%对14.3%)比较无显著性差异(P>0.05)。结论应用艾米替诺福韦联合甘草酸二铵治疗CHB患者可能促进肝功能指标的恢复,安全性良好。

关键词: 慢性乙型肝炎, 艾米替诺福韦, 甘草酸二铵, 治疗

Abstract: Objective The aim of this study was to investigate the clinical efficacy of tenofovir amibufenamide (TMF) in combination with diammonium glycyrrhizinate in treatment of patients with chronic hepatitis B (CHB). Methods A total of 112 patients with CHB were enrolled in our hospital, and were randomly assigned to receive oral TMF in 56 cases in the control group or TMF in combination with diammonium glycyrrhizinate in another 56 cases in the observation group for 48 weeks. Serum HBV DNA loads were detected by fluorescence quantitative PCR. Serum and blood parameters were routinely obtained for calculation of fibrosis index based on the 4 factors (FIB-4). Lliver stiffness measurement (LSM) was measured by Fibroscan. Results At presentation, serum HBV DNA loads in the two groups were(7.3±1.2)lg copies/mL and (7.5±1.3)lg copies/mL(P>0.05), by end of 48-week treatment, they were (1.3±0.2)lg copies/mL and (1.3±0.3)lg copies/mL(P>0.05), and serum HBV DNA negative rates in the two groups were both 100.0%(P>0.05); serum ALT and AST in the observation group were (39.6±1.1)U/L and (34.2±14.5)U/L, both significantly lower than [(54.2±5.6)U/L and (43.8±16.3)U/L, respectively, P＜0.05] in the control; the FIB-4 score was (1.8±0.3), much lower than [(2.1±0.4),P＜0.05] in the control, while the LSM[(6.7±1.0)kPa vs. (6.8±1.3)kPa] were not significantly different between the two groups (P>0.05); incidences of adverse effects in the two groups(17.9% vs. 14.3%)was not significantly different (P>0.05). Conclusion The combination of TAF and diammonium glycyrrhizinate in the treatment of patients with CHB is satisfactory, which might improve liver function tests normal.

Key words: Hepatitis B, Tenofovir amibufenamide, Diammonium glycyrrhizinate, Therapy

许广丽, 洪正飞, 施庆岳, 高春梅, 周长燕. 艾米替诺福韦联合甘草酸二铵治疗慢性乙型肝炎患者临床疗效研究^*[J]. 实用肝脏病杂志, 2026, 29(1): 25-28.

Xu Guangli, Hong Zhengfei, Shi Qingyue, et al. Clinical efficacy of tenofovir amibufenamide in combination with diammonium glycyrrhizinate in treatment of patients with chronic hepatitis B[J]. Journal of Practical Hepatology, 2026, 29(1): 25-28.

参考文献

[1] Cho H,Lee YB, Ha Y, et al. Changes in liver stiffness values assessed using transient elastography in chronic hepatitis B patients treated with tenofovir disoproxil fumarate: a prospective observational study. BMC gastroenterol, 2023, 23(1):210.
[2] 刘雨莹,张娇珍,周海娟,等.替诺福韦治疗不同HBV基因型慢性乙型肝炎患者疗效研究.实用肝脏病杂志,2022,25(4):492-495.
[3] Lee SW, Choi J, Kim SU, et al. Entecavir versus tenofovir in patients with chronic hepatitis B: enemies or partners in the prevention of hepatocellular carcinoma. Clin Mol Hepatol, 2021, 27(3):402.
[4] Yip TCF, Lai JCT, Yam TF, et al. Long-term use of tenofovir disoproxil fumarate increases fracture risk in elderly patients with chronic hepatitis B. J Hepatol, 2024, 80(4):553-563.
[5] Gupta SK, Post FA, Arribas JR, et al. Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials. AIDS, 2019, 33(9):1455-1465.
[6] 杨红梅,邱铖,黄宇超,等.恩替卡韦联合甘草酸二铵肠溶胶囊治疗慢性乙型病毒性肝炎的临床研究.中国临床药理学杂志,2023,39(17):2440-2444.
[7] Liu Y, Guo W, Li M. Diammonium glycyrrhizinate preparation for liver function recovery in chronic hepatitis B in China: a meta-analysis with trial sequential analysis. Curr Pharm Des, 2022, 28(25): 2089-2112.
[8] Wang J, Zhang P, Liao J, et al. Association ofα-fetoprotein levels with liver stiffness measurement in outpatients with chronic hepatitis B. Biosci Rep, 2021, 41(1):BSR20203048.
[9] 中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2022年版).实用肝脏病杂志,2023,26(3):S1-S22.
[10] 中国肝炎防治基金会,中华医学会感染病学分会,中华医学会肝病学分会和中国研究型医院学会肝病专业委员会.瞬时弹性成像技术诊断肝纤维化专家共识(2018年更新版).中华肝脏病杂志,2019,27(3):182-191.
[11] Yu Y, Cui X, Zhao J, et al. Effect of entecavir combined with adefovir dipivoxil on clinical efficacy and TNF‐α and IL‐6 levels in patients with hepatitis B cirrhosis. J Oncol, 2021, 2021(1):9162346.
[12] Zheng H, Wang Y, Wang FZ, et al. New progress in HBV control and the cascade of health care for people living with HBV in China: evidence from the fourth national serological survey, 2020. Lancet Reg Health West Pac, 2024, 51:101193.
[13] Peng WT, Jiang C, Yang FL, et al. Tenofovir amibufenamide vs tenofovir alafenamide for treating chronic hepatitis B: A real-world study. World J Gastroenterol, 2023, 29(44):5907.
[14] 高丽娟,李永库,董新颖,等.艾米替诺福韦治疗慢性乙型肝炎患者疗效初步研究.实用肝脏病杂志,2023,26(6):789-792.
[15] Meng LY, Yang CT, Bao JF, et al. Effectiveness and safety of tenofovir amibufenamide in chronic hepatitis B patients. World J Gastroenterol, 2024, 30(26):3261-3263.
[16] Zhang Y, Li H, Liu X, et al. Integrating metabolomics and network pharmacology to decipher the hepatoprotectiveeffect mechanisms of magnesium isoglycyrrhizinate injection. Curr Issues Mol Biol, 2023, 46(1):279-298.
[17] Choi J, Tayob N, Lim YS. Detecting early hepatocellular carcinoma in patients with chronic hepatitis B using longitudinalα-fetoprotein screening. Clin Gastroenterol Hepatol, 2023, 21(6):1590-1597.
[18] Jiang ML, Xu F, Li JL, et al. Clinical features of abnormalα-fetoprotein in 15 patients with chronic viral hepatitis B after treatment with antiviral drugs. World J Hepatol, 2025, 17(1):100392.
[19] Huang C, Lu Y, Wang Z, et al. Correlation between clinical indicators and liver pathology in children with chronic hepatitis B. Biomedicines, 2024, 12(12):2903.
[20] He X, Peng X, Zhang S, et al. Hepatoprotective effect of diammonium glycyrrhizinate and neuroprotective effect of piperazine ferulate on AmB-induced liver and kidney injury by suppressing apoptosis in vitro and in vivo. Toxicon, 2024, 246: 107795.
[21] Zoulim F, Chen PJ, Dandri M, et al.Hepatitis B virus DNA integration: Implications for diagnostics, therapy, and outcome. J Hepatol,2024,81(6):1087-1099.
[22] Trépo C, Chan HL, Lok A. Hepatitis B virus infection. Lancet, 2014,384(9959):2053-2063.
[23] Lok ASF.Toward a functional cure for hepatitis B. Gut Liver, 2024, 18(4):593-601.
[24] Fan R, Li G, Yu N, et al. aMAP score and its combination with liver stiffness measurement accurately assess liver fibrosis in chronic hepatitis B patients. Clin Gastroenterol Hepatol, 2023, 21(12):3070-3079.
[25] Yakut A, Aladag M. Noninvasive tests to assess liver stiffness in patients with chronic hepatitis B: APRI, FIB‐4, and FIB‐5 scores. Int J Clin Pract, 2024, 2024(1):5540648.
[26] Zhang Q, Cai DC, Hu P, et al. Low-level viremia in nucleoside analog-treated chronic hepatitis B patients. Chin Med J (Engl), 2021, 134(23):2810-2817.

艾米替诺福韦联合甘草酸二铵治疗慢性乙型肝炎患者临床疗效研究^*

Clinical efficacy of tenofovir amibufenamide in combination with diammonium glycyrrhizinate in treatment of patients with chronic hepatitis B

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	黎健, 罗磊, 杨文龙. 丙型肝炎微消除研究进展^*[J]. 实用肝脏病杂志, 2026, 29(1): 9-12.
[2]	王金平, 赵霞, 李伟明, 孙小惠, 王梦瑶, 李媛. 肝脏硬度检测联合血清肝纤维化标志物评估慢性乙型肝炎患者肝纤维化程度价值研究^*[J]. 实用肝脏病杂志, 2026, 29(1): 17-20.
[3]	孙雷, 陈雅倩, 曹智, 董淦功. 富马酸替诺福韦二吡呋酯联合复方甘草酸苷片治疗慢性乙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2026, 29(1): 21-24.
[4]	相宇峰, 蒋云飞, 苗永宾. 恩替卡韦联合六味五灵片治疗慢性乙型肝炎患者疗效初步研究^*[J]. 实用肝脏病杂志, 2026, 29(1): 29-32.
[5]	孙志伟, 陈小桥, 姜舒亚, 施科, 朱炜杰. 更昔洛韦联合谷胱甘肽治疗儿童巨细胞病毒性肝炎疗效研究^*[J]. 实用肝脏病杂志, 2026, 29(1): 37-40.
[6]	臧文军, 王荔, 张霞. 五灵胶囊治疗代谢相关脂肪性肝炎患者临床疗效研究^*[J]. 实用肝脏病杂志, 2026, 29(1): 65-68.
[7]	段后张, 郑扬, 陈旭峰, 汤小龙, 汪程龙. 球囊阻断逆行经静脉闭塞术治疗乙型肝炎肝硬化并发胃静脉曲张患者疗效研究^*[J]. 实用肝脏病杂志, 2026, 29(1): 81-84.
[8]	倪思远, 李鹏, 王浩, 杨银川. 阿伐曲泊帕短期治疗肝硬化并发脾功能亢进症患者疗效与安全性分析^*[J]. 实用肝脏病杂志, 2026, 29(1): 97-100.
[9]	肖颖, 金涛, 蒋圣君. 人血白蛋白联合乳果糖和门冬氨酸鸟氨酸治疗肝硬化并发肝性脑病患者疗效研究^*[J]. 实用肝脏病杂志, 2026, 29(1): 101-104.
[10]	周圣辉, 李琪, 丁惠国. 原发性胆汁性肝硬化并发食管胃底静脉曲张破裂出血患者临床特征及预后分析[J]. 实用肝脏病杂志, 2026, 29(1): 105-108.
[11]	丁靖诺, 赵卫峰, 赵法之. 急性门静脉血栓形成诊治经验分享:15例病例报道与文献复习[J]. 实用肝脏病杂志, 2026, 29(1): 113-116.
[12]	王梦云, 赵青, 赵正宇, 左小华, 刘红阳. 能谱CT虚拟平扫评估TACE术治疗肝细胞癌患者临床效果价值研究^*[J]. 实用肝脏病杂志, 2026, 29(1): 121-124.
[13]	朱超凡, 加静, 王丹. 癌组织KK-LC-1表达对靶向和免疫治疗手术切除的肝细胞癌患者预后的影响^*[J]. 实用肝脏病杂志, 2026, 29(1): 125-128.
[14]	王颖, 曾剑萍, 殷贵强, 温希, 贺凯. PTGD术后LC手术治疗急性重症胆囊炎患者时机选择探讨^*[J]. 实用肝脏病杂志, 2026, 29(1): 149-152.
[15]	姚羽, 宁波. 肝硬化门静脉血栓形成机制、自发性再通和抗凝治疗研究进展^*[J]. 实用肝脏病杂志, 2025, 28(6): 801-804.